Psychedelic Therapy: A Primer for Primary Care Clinicians – Part III. N,N-dimethyltryptamine (DMT) and Ayahuasca
Abstract
<p>Background: N,N-dimethyltryptamine (DMT) is a naturally-occurring serotonergic psychedelic found in natural plants around the globe. As the main psychoactive component in ayahuasca, which also contains monoamine oxidase (MAO) inhibitors, DMT has been consumed as plant-based brew by indigenous peoples for centuries. Further research is required to delineate the therapeutic utility of DMT.Areas of Uncertainty: Although previous research has shown that DMT is synthesized endogenously, it may not be produced at physiologically relevant concentrations. Additionally, the phenomenological similarities between the DMT-induced state and near-death experiences led to the popular hypothesis that endogenous DMT is released during the dying process; however, this hypothesis continues to be debated. Generally, DMT and ayahuasca appear to be physiologically and psychiatrically safe, though ayahuasca is known to cause transient vomiting.Therapeutic Advances: A double-blind, randomized, placebo-controlled trial showed that, within one week, ayahuasca causes remission in 36% of patients with treatment-resistant depression. According to top-line results from a recent Phase IIa trial, 57% of patients with major depressive disorder experienced remission 12 weeks after receiving a single dose of DMT. <h4>Conclusions:</h4> DMT requires further research to understand its therapeutic and clinical potential as a psychedelic. Given its possible endogenous role in human physiology, further research is also needed to understand DMT’s role in human biology, behaviour, and consciousness.</p>
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.